stockrow
Friday 6 November 2026
Export NAGE’s income statement to Excel — free account
Niagen Bioscience, Inc.
NAGE Consumer Defensive Packaged Foods
Niagen Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $129.4 million, up 29.9% from fiscal 2024.
- Revenue
- −20.0%
- EPS
- −124.7%
- Free cash flow
- −28.4%
Quarter to September 2026, against a year earlier
2.07
0.04
−1.90%
Follow NAGE
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
27.65 | 18.38 | 15.95 | 23.32 |
P/S ratio |
3.89 | 2.70 | 1.96 | 1.89 | |
P/FCF ratio |
38.17 | 35.64 | 22.09 | 23.43 | |
P/Operating CF |
741.64 | (295.17) | 91.28 | 88.04 | |
P/B ratio |
6.58 | 4.28 | 3.07 | 2.78 | |
Price to Tangible BV |
7.11 | 4.59 | 3.28 | 2.97 | |
EV/Sales |
3.40 | 2.21 | 1.46 | 1.34 | |
EV/EBITDA |
25.82 | 20.61 | 16.26 | 27.96 | |
EV/Operating CF |
32.63 | 65.00 | 31.63 | 33.49 | |
EV/FCF |
33.40 | 29.10 | 16.43 | 16.57 | |
Quick Ratio |
3.74 | 3.49 | 5.00 | 4.52 | |
Current Ratio |
4.86 | 4.61 | 6.50 | 5.93 | |
Net Debt/EBITDA |
(15.12) | (35.64) | (67.35) | 53.59 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.48 | 1.33 | 1.30 | 1.18 | |
Operating CF/Net income |
0.16 | (0.19) | 2.88 | (2.24) | |
Capex/Depreciation |
(0.51) | 19.72 | (0.31) | (1.89) | |
Research and Development Expense of Revenue |
5.05% | 4.71% | 5.08% | 6.60% | |
Selling, General and Administrative Expense of Revenue |
52.87% | 53.76% | 57.41% | 62.14% | |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.05 | 0.05 | |
Share Based Compensation of Revenue |
5.17% | 5.45% | 5.78% | 5.60% | |
Graham Net Nets |
0.13 | 0.21 | 0.29 | 0.32 | |
Graham Number |
2.24 | 2.36 | 2.16 | 1.72 | |
Earnings Yield |
3.62% | 5.44% | 6.27% | 4.29% | |
Free Cash Flow Yield |
2.62% | 2.81% | 4.53% | 4.27% | |
Revenue per Share |
0.43 | 0.39 | 0.38 | 0.34 | |
Operating CF per Share |
0.01 | (0.01) | 0.03 | 0.03 | |
Capex per Share |
0.00 | 0.07 | 0.00 | (0.01) | |
Free Cash Flow per Share |
0.01 | 0.06 | 0.03 | 0.03 | |
Cash per Share |
0.82 | 0.83 | 0.84 | 0.88 | |
Shareholders Equity per Share |
0.97 | 1.03 | 1.04 | 1.05 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.97 | 1.03 | 1.04 | 1.05 | |
Free Cash Flow |
0.58 | 4.55 | 2.68 | 2.08 | |
Working Capital |
76.89 | 82.30 | 82.74 | 83.31 | |
Capital Expenditures |
(0.10) | 5.74 | (0.09) | (0.55) | |
Net Current Asset Value |
66.93 | 73.12 | 73.73 | 74.60 | |
EV/EBIT |
27.07 | 21.99 | 17.75 | 34.24 | |
Capex to Sales |
0.00 | (0.18) | 0.00 | 0.02 | |
Price to Operating Income |
30.93 | 26.94 | 23.88 | 48.40 | |
| Other line items | |||||
Average Receivables |
8.75 | 10.06 | 9.12 | 7.67 | |
Average Payables |
9.66 | 11.95 | 11.56 | 12.12 | |
Average Inventory |
14.81 | 17.60 | 17.52 | 19.66 | |
Average Assets |
87.34 | 97.83 | 99.06 | 103.42 | |
Average Common Equity |
61.31 | 68.84 | 73.36 | 76.88 |
Columns are period end dates · fundamentals updated 6 Nov 2026